Prognosis of cT4aNxMx p16-Positive Sinonasal SCC
p16-positive sinonasal squamous cell carcinoma at cT4a stage carries a significantly better prognosis than p16-negative disease, with 5-year overall survival approaching 100% and relapse-free survival of 90% in p16-positive patients, though the T4a designation itself indicates locally advanced disease requiring aggressive multimodal treatment. 1
Prognostic Factors in Your Clinical Scenario
Impact of p16 Status
The most critical prognostic factor in your patient is the p16-positive status, which fundamentally changes the expected outcomes:
- Overall survival: p16-positive sinonasal SCC demonstrates 100% 5-year overall survival compared to significantly worse outcomes in p16-negative disease 1
- Relapse-free survival: 90% at 5 years for p16-positive tumors 1
- Disease-free survival: Significantly higher in p16-positive patients (p=0.043) 2
The p16 positivity serves as a surrogate marker for transcriptionally active HPV infection (15.2% of sinonasal SCC cases), with viral integration confirmed in these tumors 1, 3. This represents a biologically distinct entity with improved treatment response.
Impact of T4a Classification
Your patient's cT4a stage indicates moderately advanced local disease with invasion beyond the primary site but without the most extensive involvement (which would be T4b). The T4a designation carries important implications:
- T4 tumors (both T4a and T4b combined) are significantly associated with worse recurrence and mortality (OR=3.967 for recurrence, OR=5.885 for mortality) 4
- However, T4a is surgically resectable, unlike T4b disease
- For T4b disease specifically, surgery plus radiotherapy yields 5-year overall survival of 44.5% versus 20.0% for radiotherapy alone (p=0.004) 5
The combination of T4a stage with p16-positive status creates a mixed prognostic picture where the favorable biology (p16-positive) may substantially mitigate the adverse anatomic extent (T4a).
Unknown Nodal and Metastatic Status (NxMx)
The unknown nodal and distant metastatic status requires immediate clarification:
- Nodal staging: Cervical lymph node involvement significantly worsens prognosis and is associated with decreased survival 4
- Distant metastases: Must be ruled out before curative-intent treatment, as sinonasal SCC can metastasize to bone (20%), lung (13%), and liver (9%) 6
- Screening for pulmonary metastases should be performed with CT chest with IV contrast, not chest radiography (sensitivity only 28% for CXR versus CT) 6
Treatment Implications
Surgery plus radiotherapy is the standard approach for T4a disease and should be pursued aggressively given the favorable p16-positive biology:
- Multimodal therapy (surgery + radiotherapy ± chemotherapy) provides superior outcomes compared to definitive radiotherapy alone 5
- The p16-positive status suggests excellent treatment response potential
- Complete surgical resection with negative margins is critical, as free-surgical margin status is independently associated with better survival 4
Key Clinical Considerations
Anatomic Location Matters
p16-positive sinonasal SCC occurs significantly more commonly in the nasal cavity rather than paranasal sinuses 1, 3. Nasal cavity primaries allow:
- Earlier detection
- More feasible complete surgical resection with clear margins
- Better overall outcomes
This anatomic predilection partially explains the improved prognosis in p16-positive disease 3.
Confirmation of p16 Status
Ensure p16 testing was performed correctly:
- 70% nuclear and cytoplasmic staining cutoff for positivity 7
- Consider confirmatory HPV RNA in situ hybridization (RNAscope), as p16 can be falsely positive 3, 8
- Recent 2025 CAP guidelines emphasize standardized HPV testing in sinonasal SCC 8
Pitfalls to Avoid
- Do not rely on chest radiography for metastatic workup—use CT chest with IV contrast 6
- Do not assume p16 positivity alone guarantees excellent outcomes without addressing the T4a extent—aggressive local therapy is still mandatory
- Do not delay nodal staging—complete MRI or CT imaging of the neck is essential before treatment planning 6
Expected Outcomes Summary
For your cT4a p16-positive patient (assuming N0M0 after complete staging):
- 5-year overall survival: Potentially approaching 90-100% based on p16-positive status 1
- 5-year relapse-free survival: Approximately 90% 1
- These outcomes assume complete surgical resection with negative margins plus adjuvant radiotherapy
If nodal disease is present or surgical margins are positive, prognosis worsens substantially despite p16-positive status.
The T4a designation requires aggressive treatment, but the p16-positive biology provides substantial reason for optimism if complete resection can be achieved 1, 2.